Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
06 nov. 2023 12h00 HE
|
NeuroQure
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- NeuroQure has embarked on a transformative journey aimed at revolutionizing the treatment landscape for Fragile X Syndrome and Autism Spectrum...
SciSparc Granted Patent for its Core Technology From the Australian Patent Office
24 oct. 2023 07h20 HE
|
SciSparc Ltd
The Company's most recent patent further solidifies its position within the cannabis sector, complementing existing grants in the U.S., Europe, and other key jurisdictions TEL AVIV, Israel, Oct. ...
Verbal Beginnings to Open New Early Intervention Comprehensive Autism Services Center in Frederick, MD
09 août 2023 09h00 HE
|
Verbal Beginnings
FREDERICK, Md., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Verbal Beginnings, a leading provider of comprehensive Autism services is thrilled to announce the opening of a new location in Frederick, Maryland,...
PharmAla Received Guidance on ALA-002 from MHRA; Launches Clinical Program with University of Sydney
20 juil. 2023 09h07 HE
|
PharmAla Biotech
VANCOUVER, British Columbia, July 20, 2023 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:PMBHF), a biotechnology company focused on the research,...
GCANRx Announces Submission of Phase 2 Clinical Trial Application to Treat Autism Related Spectrum Disorders
07 oct. 2022 09h20 HE
|
The Greater Cannabis Company, Inc.
BALTIMORE, Oct. 07, 2022 (GLOBE NEWSWIRE) -- Greater Cannabis Company, Inc. (“GCANRx” or the “Company”) (OTC: GCAN) a biopharmaceutical company pioneering development of next generation cannabinoid...
Zynerba Pharmaceuticals Announces Positive Top Line Results from Exploratory Open Label Phase 2 BRIGHT Trial of Zygel in Autism Spectrum Disorder
27 mai 2020 06h45 HE
|
Zynerba Pharmaceuticals, Inc.
- The BRIGHT Trial Achieved Statistically Significant and Clinically Meaningful Improvements from Baseline in All Subscales of the Aberrant Behavior Checklist - - Safety Data Reinforce...
Zynerba Pharmaceuticals Presents Data Showing that the Baseline Characteristics of Patients in Phase 2 BRIGHT Trial in Autism Spectrum Disorder Indicate a Moderate-to-Severe Study Population
03 mars 2020 12h07 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., March 03, 2020 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and...
Q BioMed Files for Orphan Drug Designation with U.S. FDA for Autism Spectrum Disorder Subtype
28 juin 2019 08h32 HE
|
Q BioMed Inc.
Currently no effective treatment exists for the 20,000 children in the U.S. and 250,000 born worldwide each year with pediatric minimally verbal autism (PMVA) NEW YORK, June 28, 2019 (GLOBE...
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with Cannabidiol
11 juin 2019 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
DEVON, Pa., June 11, 2019 (GLOBE NEWSWIRE) -- Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare...
Zynerba Pharmaceuticals Initiates Phase 2 Trial of Zygel™ in Autism Spectrum Disorder
07 mars 2019 07h00 HE
|
Zynerba Pharmaceuticals, Inc.
- Topline Data from BRIGHT Study Expected in the First Half 2020 - - Company Selects Zygel™ as Brand Name for ZYN002 CBD Transdermal Gel - DEVON, Pa., March 07, 2019 (GLOBE NEWSWIRE) -- Zynerba...